Glenmark launches Tiogiva, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name - Tiogiva in UK

Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult. There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease1 .

According to data from IQVIA, Tiotropium DPI had a market size of US$ 450 Mn in the EU in the 12 month period ended September 2020. Glenmark’s subsidiary, Glenmark Pharmaceuticals Europe Limited had entered into a strategic, exclusive inlicensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and UK in August 2018.

Glenmark is planning subsequent launches of the product across markets in Western Europe under the brand name Tiogiva in Ireland, Sweden, Finland and Norway; Tavulus in Denmark, Spain and Netherlands; and Tiotropium Glenmark in Germany. Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler and is used in the treatment of COPD.

This is the second inhalation product in-licensed by Glenmark for the European market after Stalpex® (Fluticasone/ Salmeterol) dry powder inhaler.

Tags : #LatestJune15News #LatestGlenmarknews #TraetmentofCOPD #Treatmentoflungs

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026